ABSTRACT
Electroconvulsive therapy remains the best option for treatment-resistant depressive episodes. A rare, but potentially dangerous, complication is tardive seizures, which occur after the patient has already stopped convulsing from the electroconvulsive therapy and has recovered full consciousness. We have decided to report this case, which many psychiatrists and psychiatry residents may not be familiar with, to heighten the awareness of the condition because it has ramifications in terms of safe management of the patients concerned.
Subject(s)
Depressive Disorder, Major/therapy , Electroconvulsive Therapy/adverse effects , Seizures/etiology , Anticonvulsants/therapeutic use , Humans , Male , Middle Aged , Seizures/drug therapy , Time FactorsSubject(s)
Antipsychotic Agents/therapeutic use , Dibenzothiazepines/therapeutic use , Haloperidol/analogs & derivatives , Research Design , Schizophrenia/prevention & control , Administration, Oral , Antipsychotic Agents/administration & dosage , Drug Administration Schedule , Haloperidol/administration & dosage , Haloperidol/therapeutic use , Humans , Injections , Psychotic Disorders/drug therapy , Psychotic Disorders/prevention & control , Quetiapine Fumarate , Research Design/standards , Sample Size , Schizophrenia/drug therapy , Treatment OutcomeABSTRACT
Post-traumatic stress disorder (PTSD) is a severe and disabling psychiatric syndrome. With the advent of selective serotonin reuptake inhibitors (SSRIs), major strides have been made in the realms of pharmacotherapy. The multiplicity of symptom complex includes specific target symptoms, such as intrusiveness, aggression, sleep disturbances, and co-existing psychotic symptoms. Consequently, atypical antipsychotics gradually have been gaining ground in terms of adjunctive utilization. The purpose of this review is to look into the available evidence for their adjunctive use in this chronic disorder.
ABSTRACT
Is there any evidence that lofexidine is as effective as and better tolerated than clonidine for opiate detoxification? Could lofexidine be safely combined with other agents in the management of withdrawal? The purpose of this review is to seek answers to these postulates by using evidence-based testimony.
